



Peer Review Publication of Agluna® Clinical Outcome Data

Oxford, 13 February 2015 ... Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to report the publication in a leading peer review orthopaedic journal of the case-control study demonstrating significant infection rate reduction in high-risk patients receiving Agluna® treated custom limb salvage devices. The Agluna® technology is supplied by Accentus Medical under licence to Stanmore Implants on its custom (patient specific) limb salvage devices.

Published in February edition of The Bone & Joint Journal

<http://www.bjj.boneandjoint.org.uk/content/97-B/2/252.abstract>

the clinical paper reports a case-control study undertaken at the Royal Orthopaedic Hospital, Birmingham, in which 85 patients receiving Agluna® treated tumour implants between 2006 and 2011 were matched with 85 control patients receiving identical un-treated implants between 2001 and 2011.

The key reported clinical outcomes are as follows:

- Overall reduction in post-operative infection rates from 22.4% in the control group to 11.8% in the Agluna® group;
- Success rates with DAIR (debridement, antibiotics and implant retention) increased from 31.6% (control group) to 70% (Agluna® group);
- Persistent periprosthetic infection necessitating device removal, amputation or chronic antibiotics suppression reduce from 15.3% (control group) to 3.5% (Agluna® group);
- Success rates with two-stage revisions increased from 57.1% (control group) to 85% (Agluna® group).

Philip Agg, Chief Executive, said *"We are delighted that evidence of the very positive clinical outcomes being experienced by clinical end users of the Agluna® technology has now been published in The Bone & Joint Journal. Devices with Agluna® surface modification are demonstrating the clinical benefits of optimising surface concentration and release profile of silver ions. We are now accelerating broader commercialisation of this unique technology in a range of medical devices sectors, including joint reconstruction, trauma, dental, craniomaxillofacial, spine and cardiac. We look forward to bringing benefits of Agluna® to clinical end users in these growth sectors."*

-ends-

For further information, please contact:

Lynne Trowbridge

T: +44 (0)20 7457 2861

Email: AccentusMedical@instinctif.com

About Agluna®

Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is an electrochemical process involving high voltage anodisation of the titanium implant in phosphoric acid, followed by incorporation of silver ions from an aqueous solution. Agluna® is protected by several patent families registered in major global territories.

About Accentus Medical

Accentus Medical is a global leader in delivery of innovative, silver-based anti-microbial surface treatments and biocompatible coatings on implantable medical devices. The company combines a long history of expertise in surface technologies, with dedicated research and development of new technologies for the medical device industry. Based at the historic Harwell Oxford campus, Accentus Medical has provided expertise in surface technologies to the orthopaedic device industry since the 1970s, serving major orthopaedic and medical device manufacturers worldwide.

The company has two principal technology platforms: Agluna® silver anti-microbial surface treatment for prevention and control of post-operative infection, and Acusure® plasma spray coating for improving biocompatibility and durability of implants. These technologies are supplied to customers at Accentus Medical's ISO13485:2012 and ISO9001:2008 accredited facility. Accentus Medical is also very well known for the medical device testing programmes offered by its in-house test laboratories. Manufacturers have been utilising test results provided by the company for many years as part of device homologation files all over the world.

For further information, please visit: www.accentus-medical.com